(DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 15 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)(DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?PR NewswireJanuary 10, 2020ReblogShareTweetShareSAN DIEGO, Jan. 10, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dermira, Inc. (NASDAQ: DERM) ("Dermira") breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company ("Lilly").On January 10, 2020, Dermira announced that it had signed a definitive merger agreement with Lilly. Under the terms of the merger agreement, Dermira shareholders will receive $18.75 in cash per share.The investigation concerns whether the Dermira board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Dermira shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given one Wall Street analyst has a $29.00 price target on the stock. The 52-week high for Dermira was $19.30. If you are a shareholder of Dermira and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.Additionally, you can [Click here to join this action]. There is no cost or obligation to you.About Johnson Fistel, LLP:Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.Contact:Johnson Fistel, LLPJim Baker, 619-814-4471jimb@johnsonfistel.com [Click here to join this action]CisionMoreView original content:http://www.prnewswire.com/news-releases/derm-alert-johnson-fistel-investigates-proposed-sale-of-dermira-inc-is-19-30-a-fair-price-300984903.htmlSOURCE Johnson Fistel, LLPReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMincor Resources (ASX:MCR) Is In A Strong Position To Grow Its BusinessSimply Wall St.What the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoEiffage SA Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next YearSimply Wall St.Loan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceU.S. airlines suspend flights over coronavirus fearsYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance